Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use. The European-based company is developing next-generation antibody therapeutics for the treatment of cancer. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

VIBE BIO ANNOUNCED THE LAUNCH TO DEVELOP NOVEL TREATMENTS FOR RARE DISEASES

Vibe Bio | June 23, 2022

news image

Vibe Biotechnology Inc., a biotechnology company committed to identifying, funding, and developing promising treatments for rare diseases, announced officially launching with $12 million in funding to advance its community-driven approach to transforming drug development for patients with rare diseases. Vibe Bio plans on building a global community of scientists, researchers, patients, and partners with an aim to find cures for rare diseases by efficiently using a decentralized au...

Read More

Cell and Gene Therapy

NEUEXCELL THERAPEUTICS AND SPARK THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION AGREEMENT TO DEVELOP A NOVEL GENE THERAPY FOR HUNTINGTON'S DISEASE

NeuExcell Therapeutics | September 13, 2021

news image

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...

Read More

Cell and Gene Therapy

CAPSTAN THERAPEUTICS LAUNCHES WITH $165 MILLION TO DELIVER ON THE CLINICAL PROMISE OF PRECISE IN VIVO CELL ENGINEERING

Capstan | September 15, 2022

news image

Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with $165 million in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy, combining the power of cell therapy with the precision of genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan’s foundational precision in vivo e...

Read More

Industrial Impact, Medical

PAIGE AND VISIOPHARM WORK TOGETHER TO DELIVER ADVANCED AI CANCER DIAGNOSTIC SUPPORT THROUGH THE PAIGE PLATFORM

Businesswire | May 05, 2023

news image

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications to assist in diagnosing cancer, announced it is working with Visiopharm, an artificial intelligence (AI)-driven precision pathology software provider, to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio™, Paige’s AI-powered clinical worklist, a...

Read More
news image

Medical

VIBE BIO ANNOUNCED THE LAUNCH TO DEVELOP NOVEL TREATMENTS FOR RARE DISEASES

Vibe Bio | June 23, 2022

Vibe Biotechnology Inc., a biotechnology company committed to identifying, funding, and developing promising treatments for rare diseases, announced officially launching with $12 million in funding to advance its community-driven approach to transforming drug development for patients with rare diseases. Vibe Bio plans on building a global community of scientists, researchers, patients, and partners with an aim to find cures for rare diseases by efficiently using a decentralized au...

Read More
news image

Cell and Gene Therapy

NEUEXCELL THERAPEUTICS AND SPARK THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION AGREEMENT TO DEVELOP A NOVEL GENE THERAPY FOR HUNTINGTON'S DISEASE

NeuExcell Therapeutics | September 13, 2021

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...

Read More
news image

Cell and Gene Therapy

CAPSTAN THERAPEUTICS LAUNCHES WITH $165 MILLION TO DELIVER ON THE CLINICAL PROMISE OF PRECISE IN VIVO CELL ENGINEERING

Capstan | September 15, 2022

Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with $165 million in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy, combining the power of cell therapy with the precision of genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan’s foundational precision in vivo e...

Read More
news image

Industrial Impact, Medical

PAIGE AND VISIOPHARM WORK TOGETHER TO DELIVER ADVANCED AI CANCER DIAGNOSTIC SUPPORT THROUGH THE PAIGE PLATFORM

Businesswire | May 05, 2023

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications to assist in diagnosing cancer, announced it is working with Visiopharm, an artificial intelligence (AI)-driven precision pathology software provider, to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio™, Paige’s AI-powered clinical worklist, a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us